DOJ Joins Qui Tam Suits Over Off-Label Natrecor Use

Law360, New York (February 19, 2009, 12:00 AM EST) -- The U.S. Department of Justice has decided to intervene in two qui tam suits alleging that Scios Inc. and its parent company, Johnson & Johnson, engaged in off-label marketing of the cardiac drug Natrecor.

The whistleblower suits, filed by former Scios sales managers in 2005 in the U.S. District Court for the Northern District of California, allege that the off-label marketing caused false and fraudulent claims to be submitted to federal health-care programs.

According to court records, the government elected to intervene on Feb. 11, but...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.